ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer

Li, Yang-Si; Jie, Guang-Ling; Wu, Yi-Long*南方医科大学
Therapeutic Advances in Medical Oncology2023DOI: 10.1177/17588359231193726
12阅读
引用收藏
分享

摘要

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive genetic profiles and targeted therapies. However, resistance inevitably occurs, leading to disease progression after approximately 10-18 months of EGFR-TKI treatment. Platinum-based chemotherapy is the standard treatment for patients who have experienced disease progression while undergoing EGFR-TKI treatment, but its efficacy is limited. The management of extensively pretreated patients with EGFR-mutant NSCLC is becoming increasingly concerning. New agents have shown encouraging efficacy in clinical trials for this patient population, including fourth-generation EGFR-TKIs, EGFR-TKIs combined with counterpart targeted drugs, and novel agents such as antibody-drug conjugates. We review current efforts to manage extensively pretreated patients with EGFR-mutant NSCLC.

学科与关键词

关键词
EGFRnon-small-cell lung cancernovel systemic therapypretreatmenttargeted therapy
相关
加载中…
  • Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
    Lu, Hong-Lian; Jie, Guang-Ling; Wu, Yi-Long*EXPERT OPINION ON EMERGING DRUGS, 2022, 27(2): 111-126.
  • Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment
    Yuman, Yu; Yuehong, Wang; Linying, Wu; Xuanli, Xu; Hua, Zhou; Qing, Wang; Jianying, ZhouMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(5): e23712.
  • Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
    Feng, W.; Gu, W.; Zhang, H.; Lu, Y.; Gu, W.; Li, M.; Yang, S.; Zhang, J.; Ye, Z.; Lin, Q.; Liang, Y.; Chen, H.; Cheng, Y.; Yao, M.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2023
卷期
第 15 卷
页码
17588359231193726
DOI
10.1177/17588359231193726
语言
ENGLISH
成果收录
SCIE
资助标注
None.

作者

  • L

    Li, Yang-Si (第一作者)

    southern med univ

  • J

    Jie, Guang-Ling

    southern med univ

查看全部 3 位作者收起作者
  • W

    Wu, Yi-Long (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417